Condition
Non-small Cell Lung Cancer|Mesothelioma|Lung Neoplasms
Estimated Enrollment: 31
Age Group: 18 Years and older (Adult, Senior)
Gender: All
Study Type: Interventional
Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment
Study ID Numbers: 10426|H3E-MC-JMHX
Study First Received: April 18, 2006
Last Updated: June 10, 2010
Estimated Primary Completion Date: March 2009
Primary Outcome Measures:
Overview of Adverse Events|Number of Participants With Common Toxicity Criteria – National Cancer Institute Grade 3 and Grade 4 Toxicities|Pemetrexed Population Pharmacokinetics (PK): Clearance|Pemetrexed Population Pharmacokinetics: Volume of Distribution|Discontinuations Due to Adverse Events
Sponsors and Collaborators:
Eli Lilly and Company
Website Link: https://ClinicalTrials.gov/show/NCT00316225
